A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Axel Bex; Laurence Albiges; Michael Staehler; Karim Bensalah; Rachel H Giles; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Sergio Fernández-Pello; Rana Tahbaz; Yasmin Abu-Ghanem; Alessandro Volpe; Börje Ljungberg; Bernard Escudier; Thomas Powles

doi:10.1016/j.eururo.2018.08.029

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7.

Authors

Axel Bex¹, Laurence Albiges², Michael Staehler³, Karim Bensalah⁴, Rachel H Giles⁵, Saeed Dabestani⁶, Fabian Hofmann⁷, Milan Hora⁸, Markus A Kuczyk⁹, Thomas B Lam¹⁰, Lorenzo Marconi¹¹, Axel S Merseburger¹², Sergio Fernández-Pello¹³, Rana Tahbaz¹⁴, Yasmin Abu-Ghanem¹⁵, Alessandro Volpe¹⁶, Börje Ljungberg¹⁷, Bernard Escudier¹⁸, Thomas Powles¹⁹

Affiliations

¹ Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
² Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
³ Department of Urology, Ludwig-Maximilians University, Munich, Germany.
⁴ Department of Urology, University of Rennes, Rennes, France.
⁵ International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Centre Utrecht, Utrecht, The Netherlands.
⁶ Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden.
⁷ Department of Urology, Sunderby Hospital, Sunderby, Sweden.
⁸ Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
⁹ Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
¹⁰ Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
¹¹ Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
¹² Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
¹³ Department of Urology, Cabueñes Hospital, Gijón, Spain.
¹⁴ Department of Urology, Elbe Kliniken Stade, Stade, Germany.
¹⁵ Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
¹⁶ Division of Urology, Maggiore della Carita' Hospital, University of Eastern Piedmont, Novara, Italy.
¹⁷ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
¹⁸ Gustave Roussy Cancer Institute, Villejuif Cedex, France.
¹⁹ The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: thomas.powles@bartshealth.nhs.uk.

PMID: 30201510
DOI: 10.1016/j.eururo.2018.08.029

No abstract available

Publication types

Letter
Practice Guideline

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / mortality
Carcinoma, Renal Cell / pathology
Clinical Decision-Making*
Drug Approval*
Evidence-Based Medicine / standards*
Humans
Ipilimumab / adverse effects
Ipilimumab / therapeutic use*
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / mortality
Kidney Neoplasms / pathology
Nephrology / standards*
Nivolumab / adverse effects
Nivolumab / therapeutic use*
Patient Selection
Treatment Outcome
Urology / standards*

Substances

Antineoplastic Agents, Immunological
Ipilimumab
Nivolumab